RICHARD F. BAKEMEIER, M.D.; JAMES R. ANDERSON, Ph.D.; WILLIAM COSTELLO, Ph.D.; GARY ROSNER, M.S.; JOHN HORTON, M.B., Ch.B.; JOHN H. GLICK, M.D.; JOHN D. HINES, M.D.; COSTAN W. BERARD, M.D.; VINCENT T. DeVITA Jr., M.D.
Two chemotherapy regimens for treatment of patients with advanced Hodgkin's disease, BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone) and MOPP (mechlorethamine hydrochloride, vincristine, procarbazine, and prednisone), were compared in a randomized prospective study. Two hundred ninety-three patients were evaluable in the induction phase of this study. The complete remission rate with BCVPP was 76% (112/147) and with MOPP, 73% (106/146) (p = 0.51). The duration of complete remissions for previously untreated patients given BCVPP was significantly longer than that for previously untreated patients given MOPP (p = 0.02). Although hematologic toxicities were similar, BCVPP caused less gastrointestinal (p = 0.0001) and neurologic toxicity (p = 0.01) than MOPP. Previously untreated patients achieving complete remission with BCVPP survived significantly longer than those receiving MOPP (p = 0.03). As primary induction chemotherapy for advanced Hodgkin's disease, BCVPP is an effective alternative to MOPP, having equal or greater therapeutic benefit with less toxicity.
BAKEMEIER RF, ANDERSON JR, COSTELLO W, et al. BCVPP Chemotherapy for Advanced Hodgkin's Disease: Evidence for Greater Duration of Complete Remission, Greater Survival, and Less Toxicity Than with a MOPP Regimen: Results of the Eastern Cooperative Oncology Group Study. Ann Intern Med. 1984;101:447–456. doi: https://doi.org/10.7326/0003-4819-101-4-447
Download citation file:
Published: Ann Intern Med. 1984;101(4):447-456.
Emergency Medicine, Hematology/Oncology, Leukemia/Lymphoma.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use